OncoGenex Pharmaceuticals, Inc.
1522 217th Place SE
Suite 100
Bothell,
WA 98021
United States - Map
Phone: 425-686-1500
Fax: 425-686-1600
Web Site: http://www.oncogenex.ca
| OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of cancer. The companys lead candidate, OGX-011, is being evaluated in five Phase II clinical trials. OGX-011, which is also known as custirsen sodium, inhibits the production of clusterin, a protein that is over-produced in various types of cancer and in response to a range of cancer treatments, including hormone ablation therapy, chemotherapy, and radiation therapy. Its other product candidates include OGX-427, a Phase 1 clinical trial product, which is focused on reducing heat shock protein 27; and SN2310, a phase I clinical trial completed product for the treatment of cancer. The companys preclinical stage products consist of OGX-225, an inhibitor of insulin growth factor binding proteins 2 and 5; and CSP-9222, a compound from a family of caspase activators. OncoGenex Pharmaceuticals is based in Bothell, Washington. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Scott Daniel Cormack , 44
Founder, Chief Exec. Officer, Pres |
$
281.00K |
$
14.00K | Mr. Stephen Anderson , 47
Chief Financial Officer, Principal Accounting Officer and Sec. |
$
130.00K | N/A | Dr. Cindy Jacobs Ph.D., M.D., 51
Chief Medical Officer and Exec. VP |
$
309.00K | N/A | Dr. Martin Gleave MD, FRCSC, FACS, 50
Co-Founder and Chief Scientific Officer |
N/A
| N/A | Dr. Elaine Waller Pharm.D., 56
Sr. VP of Regulatory Affairs & Quality Assurance |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 
Profile
